Mumbai, August 08, 2018: Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its unaudited
- consolidated financial results for quarter ended June 30, 2018.
- Financials: Strong YoY sales growth of 12% with EBITDA growing by 12%
R&D investments at ~INR 278cr / ~7% of sales - Continued growth momentum: Strong growth across India (+22% YoY), South Africa
(+14% YoY adjusted for animal health) and API business (+48% YoY) - Key differentiated launches in the US including Isoproterenol HCI Injection and
Testosterone Cypionate Injection - Quality Focus: Received EIR for Goa & Indore Plants
Corporate Comm India(CCI Newswire)
